Overview
AthenaBIO, founded in 2022 as AthenaDAO, is a decentralized science (DeSci) organization that sources, funds and incubates women's health R&D, connecting researchers with legal, strategic, scientific and market support. It began as a Bio Protocol BioDAO, using community-held tokens to govern which projects get funded and how the resulting intellectual property is stewarded, and it still describes its funding rails in those terms — “on-chain transparent blockchain technology and incentives to fund early-stage research and biotech startups via a token held by the community”, with capital allocation done collaboratively.
Women's health is chronically under-funded relative to its disease burden, and the organization frames the gap as a market opportunity rather than a charity case — pooling community capital to de-risk early translational science that traditional grant pipelines and venture funds routinely skip. Its named research bets concentrate on ovarian aging: novel therapeutic targets with the AI drug-discovery firm Gero, the integrated stress response (ISR) pathway for ovarian follicle survival, and the cGAS–STING inflammatory pathway in reproductive aging.
From AthenaDAO to AthenaBIO
On 8 March 2026 the organization published “AthenaBIO: The first Science-First Ecosystem for Women's Health R&D”, which introduces the entity as “AthenaBIO (formerly known as AthenaDAO)”. The rename has since propagated through the public site: athenadao.co now reads “AthenaBIO” in its body copy and footer while keeping the original domain, and the organization describes itself as “a think tank and global community of researchers, funders, and advocates” rather than as a DAO. The ATH token and the community-allocation framing remain on the site.
The rename formalises a shift that began in September 2025, when AthenaDAO launched AthenaBIO as an equity vehicle to carry vetted assets through the capital-intensive phases — validation, regulation, scale — that a community treasury alone cannot underwrite. It is structured as a holding company with SPVs rather than a traditional closed-end fund, aiming to raise about $5 million against roughly 15 early-stage assets across AI-driven diagnostics, ovarian health and reproductive technology, all previously cleared by the organization's scientific review.
The founders were candid about the motive: as one put it, “your token is never going to reflect the value of what you are building” — a recurring tension in DAO tokenomics, where a freely-traded governance token's price drifts away from the value of the underlying work. The answer here was to split the two rather than pick one: keep the community layer for sourcing, education and IP governance, and route institutional capital through a separate equity structure. It is worth reading alongside VitaDAO, which met the same discovery-to-commercialization gap by pairing IP-NFTs with a pharma spinout instead of a holding company.
Funding model & track record
Through five review cohorts the organization's community has deployed roughly $1.5 million into science. Its own March 2026 count of what that bought is six labs, 20 academic fellowships, three pre-prints, three start-ups, one summit and more than 100 live events, from a Science & Deal Flow team that reports having evaluated over 430 scientific proposals across five focused cohorts. These are self-reported figures and the counts differ slightly between the organization's own posts and press coverage; treat them as an order of magnitude rather than an audited ledger.
Every asset passes the scientific-review process before capital is committed, and funded IP is held and licensed through the IP-NFT tooling built by Molecule — the same rails used by HairDAO and the rest of the Bio Protocol cohort. The community layer also publishes standalone research: a data-and-wearables report on the ownership and governance of women's health data sits alongside the funded science, and the newsletter has continued to publish through July 2026, which is the clearest available signal that the organization is operating rather than winding down.
The governance record, and when it stopped
AthenaDAO's binding votes ran on Snapshot at athenadao.eth, and the space is still readable in full whatever the organization now calls itself. It carried 18 proposals between October 2023 and September 2025, and every one of them cleared quorum – the first three against quorums of 25,000 and 250,000 ATH, the remaining fifteen against 390,646 ATH, with weight cast ranging from 213,352 to 1,857,921 ATH. Head-count turnout never exceeded 18 voters. On the measure most DAOs fail, this one did not fail once.
It stopped anyway, and the sequence is tight. ADP-013, funding a multi-hop RAG system for reproductive longevity with CoopHive, closed on 3 September 2025 with 1,857,921 ATH For, zero Against and zero Abstain from nine voters – the largest weight the space ever recorded, cast on its final proposal. Two weeks later, on 17 September 2025, the organization announced AthenaBIO as the equity vehicle described above. The rename followed on 8 March 2026. As of 18 August 2026 the space has been silent for 349 days.
Why no member restarted it is a setting rather than an attitude. The space restricts proposal creation to an author allowlist – one admin and four members, five addresses in total – which Snapshot documents as restricting proposals “to authors only” instead of validating a proposer's voting power against a threshold. ATH confers the right to vote and not the right to propose, so when the five stopped proposing there was no route by which a holder could put anything to the vote. This wiki treats that as a distinct class of proposal throttle, and AthenaDAO is one of ten DeSci spaces measured there using it.
The token outlived the governance, which is the ordinary outcome rather than a surprising one. ATH's Ethereum contract, 0xA4ff…4739, returns a totalSupply of exactly 30,000,000 with the symbol ATH; a second ATH contract on Base holds 739,944.57, the Base-side balance behind the Aerodrome liquidity ADP-005 and ADP-008 incentivised, and the Snapshot space's two token-weighted strategies sum a holder's balance across both chains. All four figures were read on-chain on 18 August 2026. What no longer exists is anything for that weight to be cast on.
How Caper approaches this
The token-versus-equity split AthenaBIO reached for is exactly the seam a caper is designed to close. On Caper, contributed capital flows into the caper's own bonding-curve treasury rather than into a free-floating token whose price detaches from the work — value accrues to the treasury itself, and members hold a participation-weighted exit claim on it. Research spending is then authorised the same way governance authorises any spend: a PAYOUT proposal that transfers a chosen currency and amount from the treasury to a lab or researcher once members vote it through. There is no separate equity vehicle to spin up, and voting weight is stake weighted by participation, so the people funding the science keep governance coupled to their exposure.